4/A: Acasti Pharma Inc.: VP Clinical Operations Reports Stock Option Grant

Carrie D'Andrea, VP of Clinical Operations at Acasti Pharma Inc., reports the acquisition of stock options.

Summary

• Carrie D'Andrea, VP of Clinical Operations at Acasti Pharma Inc., filed an amendment to a previous Form 4 regarding changes in beneficial ownership.
• The amendment corrects the signature block of the original filing from May 8, 2024.
• The report details the grant of stock options on May 6, 2024, under the Acasti Pharma Stock Option Plan.
• D'Andrea acquired 19,740 stock options with an exercise price of $2.96.
• These options vest quarterly in equal installments over a 36-month period, expiring on May 6, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. It indicates alignment of management with company goals.

Positives

• The grant of stock options aligns the interests of the VP of Clinical Operations with the company's performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key employees and align their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of quarterly installments over 36 months is a typical arrangement to encourage long-term commitment.
• Comparable companies like Amarin or Esperion also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised in the future.

Key Dates